Barclays Cuts Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00
Sangamo Therapeutics (NASDAQ:SGMO – Free Report) had its price objective lowered by Barclays from $9.00 to $5.00 in a research report released on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued reports about the stock. Royal Bank of Canada reiterated a […]
Sangamo Therapeutics (NASDAQ:SGMO – Free Report) had its price objective lowered by Barclays from $9.00 to $5.00 in a research report released on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued reports about the stock. Royal Bank of Canada reiterated a […]
